SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-122443
Filing Date
2024-11-06
Accepted
2024-11-06 17:00:29
Documents
91
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q sabs-20240930.htm   iXBRL 10-Q 2375292
2 EX-31.1 sabs-ex31_1.htm EX-31.1 23078
3 EX-31.2 sabs-ex31_2.htm EX-31.2 23141
4 EX-32.1 sabs-ex32_1.htm EX-32.1 9994
5 EX-32.2 sabs-ex32_2.htm EX-32.2 10304
6 GRAPHIC img153680404_0.jpg GRAPHIC 40808
7 GRAPHIC img153680404_1.jpg GRAPHIC 46610
  Complete submission text file 0000950170-24-122443.txt   11098686

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20240930.xsd EX-101.SCH 1758709
94 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20240930_htm.xml XML 1875495
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39871 | Film No.: 241431987
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)